TOG Review (RCOG Journal)

MRCOG Part 2

Gynaecological Oncology

Borderline ovarian tumours

Key Statistics

  • 10–20% — Of epithelial ovarian neoplasms are BOTs
  • 99.7% — 5-Yr survival, FIGO stage i
  • 2–24% — Recurrence rate range

Don't-miss facts

  1. Normal CA125 does NOT exclude a BOT; no marker or imaging test can reliably separate benign/BOT/malignant disease

  2. SBOT → cystectomy; MBOT → adnexectomy (appendicectomy only if macroscopically abnormal); full surgical staging recommended for all early-stage BOTs

  3. Micropapillary/cribriform SBOT pattern = LGSOC precursor, ↑invasive implants/lethal recurrence; invasive implants = reclassify as LGSOC

  4. No adjuvant chemo/radiotherapy role in BOT (Cochrane 2010); FSA concordance only 66–73% – rely on full staging, not FSA

  5. Recurrence 2–24% (invasive only 0.5–3.8%), can occur >10 years later → follow up beyond 5 years; manage recurrence with secondary surgery

  6. Fertility-sparing surgery/ART not contraindicated and does not worsen survival despite ↑recurrence risk; no advised delay before ART

  7. MBOT: HRT recommended if menopausal <45y; SBOT with poor-prognosis histology (micropapillary/implants/microinvasion) – no HRT recommendation, discuss at menopause MDT

  8. BOT in pregnancy: TVUSS first line; MRI (no gadolinium) from 12 weeks if indeterminate; laparoscopic approach preferred

Surgery at a glance

SBOT: cystectomy (bilateral option if bilateral) MBOT: adnexectomy ± cystectomy if bilateral

No routine lymphadenectomy or adjuvant therapy

Abbreviation Key

  • BOT — borderline ovarian tumour
  • HE4 — human epididymis protein 4
  • OC — ovarian cancer
  • CEA — carcinoembryonic antigen
  • SBOT — serous borderline ovarian tumour
  • α-FP — alpha-fetoprotein
  • MBOT — mucinous borderline ovarian tumour
  • β-HCG — beta-human chorionic gonadotrophin
  • LGSOC — low-grade serous ovarian carcinoma
  • LDH — lactate dehydrogenase
  • FIGO — International Federation of Gynaecology and Obstetrics
  • MDT — multidisciplinary team
  • TVUSS — transvaginal ultrasound scan
  • BSO/USO — bilateral/unilateral salpingo-oophorectomy
  • IOTA — International Ovarian Tumour Analysis
  • FSA — frozen section analysis
  • ADNEX — Assessment of Different Neoplasms in the Adnexa
  • ART — assisted reproductive technology
  • O-RADS — Ovarian Adnexal Reporting and Data Systems
  • HRT — hormone replacement therapy
  • CA125 — cancer antigen 125
  • NICE — National Institute for Health and Care Excellence
  • CA19-9 — carbohydrate antigen 19-9
  • RCOG — Royal College of Obstetricians and Gynaecologists
  • BGCS — British Gynaecological Cancer Society
  • ESGO/ESHRE/ESGE — European gynae- oncology/reproductive/endoscopy societies
  • CNGOF — French College of Obstetricians & Gynaecologists

Source: Baker-Rand H et al. Borderline ovarian tumours. The Obstetrician & Gynaecologist 2025;27:321–331. doi:10.1111/tog.70007

MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).

Included with a Pass Package

  • Audio overview of this guideline
  • Practice questions drawn from it
  • AI tutor answers grounded in its text
  • Your own annotations
Start free